Citation
Onofrj, M, et al. "Combining Entacapone With levodopa/DDCI Improves Clinical Status and Quality of Life in Parkinson's Disease (PD) Patients Experiencing Wearing-off, Regardless of the Dosing Frequency: Results of a Large Multicentre Open-label Study." Journal of Neural Transmission (Vienna, Austria : 1996), vol. 111, no. 8, 2004, pp. 1053-63.
Onofrj M, Thomas A, Vingerhoets F, et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J Neural Transm (Vienna). 2004;111(8):1053-63.
Onofrj, M., Thomas, A., Vingerhoets, F., Martin, W., Giménez-Roldán, S., Azulay, J. P., Bernhard, G., Schmidt, W., & Markabi, S. (2004). Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. Journal of Neural Transmission (Vienna, Austria : 1996), 111(8), 1053-63.
Onofrj M, et al. Combining Entacapone With levodopa/DDCI Improves Clinical Status and Quality of Life in Parkinson's Disease (PD) Patients Experiencing Wearing-off, Regardless of the Dosing Frequency: Results of a Large Multicentre Open-label Study. J Neural Transm (Vienna). 2004;111(8):1053-63. PubMed PMID: 15254793.
TY - JOUR
T1 - Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
AU - Onofrj,M,
AU - Thomas,A,
AU - Vingerhoets,F,
AU - Martin,W,
AU - Giménez-Roldán,S,
AU - Azulay,J-P,
AU - Bernhard,G,
AU - Schmidt,W,
AU - Markabi,S,
Y1 - 2004/05/12/
PY - 2003/08/26/received
PY - 2004/03/19/accepted
PY - 2004/7/16/pubmed
PY - 2004/12/16/medline
PY - 2004/7/16/entrez
SP - 1053
EP - 63
JF - Journal of neural transmission (Vienna, Austria : 1996)
JO - J Neural Transm (Vienna)
VL - 111
IS - 8
N2 - The efficacy of entacapone and its impact on patient quality of life (QOL) was investigated in an open-label study of 899 patients with idiopathic Parkinson's Disease (PD) experiencing wearing-off fluctuations. Patients were divided into 3 groups (3, 4 or 5 doses daily) based on their current levodopa dosage frequency. Patients received 200 mg entacapone with each levodopa/dopa-decarboxylase inhibitor (DDCI) dose, while continuing their same levodopa/DDCI dosage regimen for 4 weeks. Primary efficacy measure was the Investigators' Clinical Global Impression of Change (CGIC). Patient QoL was assessed using the validated 8-item Parkinson's Disease Questionnaire (PDQ-8). Investigators' CGIC revealed that 76.5% of entacapone treated patients experienced an improvement in global status after 4 weeks. Treatment with entacapone was also associated with improvement in patient QoL, with a mean reduction (improvement) in PDQ-8 score of 1.8 from baseline. This study confirms and extends the results of earlier studies demonstrating that, independent of dosing frequency, completing levodopa/DDCI therapy with entacapone provides clinically relevant improvements in global status and QoL in PD patients experiencing wearing-off on their current levodopa dosing frequency.
SN - 0300-9564
UR - https://www.unboundmedicine.com/medline/citation/15254793/Combining_entacapone_with_levodopa/DDCI_improves_clinical_status_and_quality_of_life_in_Parkinson's_Disease__PD__patients_experiencing_wearing_off_regardless_of_the_dosing_frequency:_results_of_a_large_multicentre_open_label_study_
L2 - https://doi.org/10.1007/s00702-004-0149-4
DB - PRIME
DP - Unbound Medicine
ER -
